Risk and Volatility
Virpax Pharmaceuticals has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500.
Profitability
This table compares Virpax Pharmaceuticals and Ayala Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Virpax Pharmaceuticals | N/A | -1,554.34% | -338.29% |
| Ayala Pharmaceuticals | N/A | N/A | N/A |
Valuation and Earnings
This table compares Virpax Pharmaceuticals and Ayala Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Virpax Pharmaceuticals | N/A | N/A | -$15.19 million | ($123.25) | 0.00 |
| Ayala Pharmaceuticals | $3.24 million | 11.05 | -$48.07 million | ($5.02) | -0.12 |
Virpax Pharmaceuticals has higher earnings, but lower revenue than Ayala Pharmaceuticals. Ayala Pharmaceuticals is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Virpax Pharmaceuticals beats Ayala Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
About Virpax Pharmaceuticals
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Receive News & Ratings for Virpax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virpax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
